NATiV3NCT04849728
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 44 versions: 44 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 40 words
- Primary completion date changed from estimate of Sep 30, 2027 to Sep 29, 2026
- Study description expanded, about 11 words
- Site details revised at 44 of 459 sites
- Minor Site details revised at 46 of 459 sitesv43
- Minor Primary and study completion pushed from Jun 30, 2027 to Sep 30, 2027
- Trial sites expanded: 434 → 459 locations
- Notable Primary and study completion pushed from Dec 30, 2026 to Jun 30, 2027
- Trial sites expanded: 428 → 434 locations
- Notable Primary and study completion dates pushed to Dec 30, 2026
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 494 to 428
Show 38 earlier versionsHide 38 earlier versions
- Minor Site details revised at 1 of 494 sitesv39
- Minor Site details revised at 1 of 494 sitesv38
- Minor Site details revised at 2 of 494 sitesv37
- Minor Site details revised at 3 of 494 sitesv36
- Minor Study sites: 493 to 494v35
- Minor Site details revised at 4 of 493 sitesv34
- Minor Site details revised at 7 of 493 sitesv33
- Minor Study sites revised (493)v32
- Minor Site details revised at 4 of 493 sitesv31
- Minor Study sites: 491 to 493v30
- Minor Site details revised at 1 of 491 sitesv29
- Minor Site details revised at 1 of 491 sitesv28
- Minor Study sites: 486 to 491v27
- Minor Study sites: 407 to 486v26
- Minor Study sites: 397 to 407v25
- Minor Study sites: 395 to 397v24
- Minor Study sites: 394 to 395v23
- Minor Study sites: 391 to 394v22
- Minor Study sites: 385 to 391v21
- Minor Study sites: 382 to 385v20
- Minor Study sites: 383 to 382v19
- Minor Study sites: 378 to 383v18
- Minor Study sites: 354 to 378v17
Notable Enrollment target: 2000 to 1000v16 Show 7 more changesShow less
- Primary completion date: Feb 2024 to Sep 30, 2025
- Eligibility criteria expanded, about 52 words
- Primary endpoints revised (2)
- Study sites: 353 to 354
- Study completion date: Sep 2028 to Sep 30, 2026
- Study description shortened, about 11 words
- Study title expanded, about 4 words
- Minor Study sites: 337 to 353v15
- Minor Study sites: 291 to 337v14
- Minor Study sites: 255 to 291v13
- Minor Study sites: 223 to 255v12
- Minor Study sites: 183 to 223v11
- Minor Study sites: 148 to 183v10
- Minor Study sites: 88 to 148v9
- Minor Study sites: 65 to 88v8
- Minor Study sites: 51 to 65v7
- Minor Study sites: 27 to 51v6
- Minor Study sites: 14 to 27v5
- Minor Study sites: 13 to 14v4
Notable Eligibility criteria shortened, about 1,045 wordsv3 Show 4 more changesShow less
- Primary endpoints: 1 to 2
- Study sites: 1 to 13
- Start date changed from estimate of Aug 2021 to Aug 19, 2021
- Interventions: Lanifibranor (Drug) to IVA337 (Drug), Placebo (Drug)
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date: Jul 2021 to Aug 2021
- Study title shortened, about 7 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --\> once a day (quaque die, QD)
3 Lanifibranor tablets 400mg with food --\> once a day (quaque die, QD)
3 Placebo to match tablets with food --\> once a day (quaque die, QD)
Drugs: IVA337, Placebo
Sites
459 sites in 24 countries
United States 194, China 71, France 27, Spain 19, Mexico 18, Germany 12, United Kingdom 12, Australia 11, Poland 11, Belgium 10, Italy 10, Israel 9, Canada 7, Argentina 6, Bulgaria 6, Netherlands 6, Portugal 6, South Africa 6, Brazil 5, Hungary 5, Chile 3, Puerto Rico 2, Ukraine 2, Czechia 1